Raffi Afeyan

Flagship Pioneering, Inc. (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts.

Ampersand Biomedicines is an American company that designs programmable medicines that work precisely where needed in the body and nowhere else. The company's computationally powered platform identifies ideal addresses for drug localization and informs the design of and-body™ therapeutics that have the optimal therapeutic effect. The result is smarter biologic medicines that target the site of disease without affecting healthy tissue or cells. Ampersand is enabling potent mechanisms to treat disease by creating and programming therapeutics that are more efficacious, without compromising on safety or tolerability. The company was founded in 2020 at Flagship Labs, a unit of Flagship Pioneering. Jason Gardner has been the CEO of the company since 2023.

Generate Biomedicines, Inc. is a drug generation company that has developed a machine learning-powered multimodality generative biology platform capable of generating new drugs on demand across a wide range of biologic modalities. Generate Biomedicines is based in Somerville, MA. The platform seamlessly integrates computational and wet lab capabilities, improving the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company's platform represents a potentially fundamental shift in what's possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. The company was founded in 2018 by Poorya Hosseini, Molly Gibson, Geoffrey von Maltzahn, Avak Kahvejian, Gevorg Grigoryan. Michael T. Nally has been the CEO of the company since 2018.

Cellarity Inc. engages in the operation of platform to design medicines targeting the full cellular and molecular complexity of disease. The company was founded by Avak Kahvejian, James J. Collins, Noubar Afeyan, and Nicholas Plugis in 2017 and is headquartered in Cambridge, MA.